Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
06/2005
06/02/2005US20050119275 Antiinflammatory agents; autoimmune disease; Alzheimer's disease; anticancer agents; antiarthritic agents; antidiabetic agents; lupus; interinflammatory agents
06/02/2005US20050119257 Cyclic sulfone containing retroviral protease inhibitors
06/02/2005US20050119250 Amino-derivatives as novel inhibitors of histone deacetylase
06/02/2005US20050119236 Cancer treatments and pharmaceutical compositions therefor
06/02/2005US20050119231 Quinolone antibiotics such as 3-Amino-1-cyclopropyl-6-fluoro-7-(3-hydroxymethyl-pyrrolidin-1-yl)-8-methoxy-1H-quinazoline-2,4-dione, used for treating gramnegative or grampositive bacterial infection in mammals
06/02/2005US20050119204 Osteopontin-related compositions and methods
06/02/2005US20050119202 Medicament to treat a fibrotic disease
06/02/2005US20050119189 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
06/02/2005US20050118698 Propagating viral particle in BHK (baby hamster kidney) and MDCK (mandine darby canine kidney) cell lines; for use as bioreactor for producing drugs and/or diagnostic agents
06/02/2005US20050118567 Method for determining sensitivity to a bacteriophage
06/02/2005US20050118566 Replicons derived from positive strand rna virus genomes useful for the production of heterologous proteins
06/02/2005US20050118281 Substantially non-colloidal solution made by combining ingredients comprising (a) water; (b) a source of free silver ions; and (c) a substantially non-toxic, substantially thiol-free, substantially water-soluble complexing agent.
06/02/2005US20050118242 Using testosterone; topical applying to skins
06/02/2005US20050118205 Artificial sweetener, a sugar sweetener and a flavoring agent to mask a bitter antibiotic such as levofloxacin
06/02/2005US20050118201 Formalin inactivated preparations of mycobacteria, e.g., M. bovis, mixed with oil-containing nonphospholipid paucilamellar lipid vesicles e.g. Novasomes (reg); can be used on immunocomprised patients
06/02/2005US20050118200 Two or more inactivated or attenuated Mycoplasma bovis biotypes, inactivated Mycoplasma alkalescens, an adjuvant and excipient; vaccinating cows; no undesirable side effects and protect against M. bovis related disease, such as contagious mastitis, respiratory pneumonia
06/02/2005US20050118196 Novel therapeutic processes for establishing or enhancing an immunized state, and compositions useful therefor
06/02/2005US20050118195 Virus causing respiratory tract illness in susceptible mammals
06/02/2005US20050118190 Staphylococcus antigen and vaccine
06/02/2005US20050118189 Mutant Hin47 protein with decreased protease activity, and a high molecular weight protein of a strain of non-typeable Haemophilus influenzae; may be combined with diphtheria or tetanus toxoids, pertussis antigens or non-virulent poliovirus; immunization; otitis media
06/02/2005US20050118188 HIV antigen and DC-cholesterol
06/02/2005US20050118181 Use of antibody against GBV-C E2 to treat human immunodeficiency virus (HIV); vaccines
06/02/2005US20050118162 Treatment of micro-organism infection
06/02/2005US20050118159 recombinant DNA molecules that express homogenous lysostaphin and host cells transformed with these DNA molecules
06/02/2005US20050118140 Madin Darby Canine Kidney cells are virally infected and cultured in suspension on an industrial scale to produce the active ingredient, and then mixed with a carrier or dilluent
06/02/2005CA2547881A1 Prevention of and countermeasures against viral infection
06/02/2005CA2546840A1 Immunization against chlamydia infection
06/02/2005CA2546836A1 Immunization against chlamydia infection
06/02/2005CA2546339A1 Antibacterial aminoquinazolidinedione derivatives
06/02/2005CA2546195A1 The use of anti biotics as vaccine adjuvants
06/02/2005CA2545935A1 Methods for modulating the th2 immune response to an antigen by adding or removing activated carbonyl groups from the antigen
06/02/2005CA2544769A1 Acremonic acid derivatives
06/01/2005EP1536008A1 2’,5’-OLIGOADENYLATE PHOSPHODIESTERASE
06/01/2005EP1535927A1 Hbv precore protein capable of forming particles
06/01/2005EP1535924A1 Novel carbapenem compounds
06/01/2005EP1535920A1 Process for preparation of 1,3-benzodioxole-2-spiro- cycloalkane derivatives
06/01/2005EP1535626A2 Actinomyces pyogenes and actinomyces pyogenes/fusobacterium necrophorum vaccines for immunizing cattle and sheep
06/01/2005EP1535620A1 The use of n-acetyl-d-glucosamine for preparing medicines for urogenital tract infection's treatment and prevention
06/01/2005EP1535065A2 Neuroprotective synergy of erythropoietin and insulin-like growth factor
06/01/2005EP1534847A1 Retroviral vector and stable packaging cell lines
06/01/2005EP1534846A1 Replicons of pestiviruses that do not express c and or e1 protein and infectious viral particles containing same, that can be used in vaccines
06/01/2005EP1534753A2 Antibody peg positional isomers, compositions comprising same, and use thereof
06/01/2005EP1534727A2 Crystalline and amorphous forms of beta-l-2 -deoxythymidine
06/01/2005EP1534725A2 Compounds and methods for inhibiting selectin-mediated function
06/01/2005EP1534717A1 Beta-lactamase inhibitor prodrug
06/01/2005EP1534708A2 Purine derivatives and their use as antiproliferative agents
06/01/2005EP1534687A1 Pyrimidine compounds
06/01/2005EP1534685A1 1h-indazole-3-carboxamide compounds as cyclin dependent kinases (cdk) inhibitors
06/01/2005EP1534681A1 Substituted quinoline ccr5 receptor antagonists
06/01/2005EP1534678A1 Pleuromutilin derivatives as antimicrobbials
06/01/2005EP1534677A1 Piperidine derivatives and their use as selective inhibitors of mip-1alpha binding to its receptor ccr1
06/01/2005EP1534676A1 Piperidinetriol derivatives as inhibitors of glycosylceramide synthase
06/01/2005EP1534674A2 Cytotoxic agents containing novel potent taxanes and their therapeutic use
06/01/2005EP1534668A1 Crystalline solid form of (2s-5z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid
06/01/2005EP1534666A1 Compounds for modulating the glycolosis enzyme complex and/or transaminase complex
06/01/2005EP1534367A1 Medicament dispenser
06/01/2005EP1534332A2 Antibodies and uses thereof
06/01/2005EP1534327A2 Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies
06/01/2005EP1534324A2 Tumor specific oligosaccharide epitopes and use thereof
06/01/2005EP1534315A2 Increasing of the resorption of substances via skin and mucous membranes
06/01/2005EP1534306A2 Defensins: use as antiviral agents
06/01/2005EP1534303A1 Antimicrobial charged polymers that exhibit resistance to lysomal degradation during kidney filtration and renal passage, compositions and method of use thereof
06/01/2005EP1534299A2 Methods for treating psychosis associated with interferon-alpha therapy
06/01/2005EP1534290A2 Novel inhibitors of kinases
06/01/2005EP1534278A2 Nitrosated proton pump inhibitors, compositions and methods of use
06/01/2005EP1534276A2 Non-nucleoside reverse transcriptase inhibitors
06/01/2005EP1534272A2 Treatment of non-allergic rhinitis by means of selective phosphodiesterase-4 inhibitors
06/01/2005EP1534263A2 Novel compounds, pharmaceutical compositions containing same, and methods of use for same
06/01/2005EP1534250A2 Electrospun amorphous pharmaceutical compositions
06/01/2005EP1534242A2 Buccal, polar or non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
06/01/2005EP1453820B1 Substituted 6h-dibenzo[c,h]chromenes as estrogenic agents
06/01/2005EP1416936B1 Thiopyrane-4-ones as dna protein kinase inhibitors
06/01/2005EP1404330B1 Substituted 8-arylquinoline pde4 inhibitors
06/01/2005EP1385847B1 Pyrazolo[1,5-a]pyridine derivatives
06/01/2005EP1351959B1 Novel pleuromutilin derivatives
06/01/2005EP1233951B1 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
06/01/2005EP1206189B1 Rotavirus vaccine formulations
06/01/2005EP1188754B1 Substituted pyrazole compounds
06/01/2005EP1178977B1 Ion channel modulating agents
06/01/2005EP1171160B1 Method and means for treating post-polio syndrome
06/01/2005EP1100878B1 Process for producing genetically modified cd34-negative adherently growing haematopoietic stem cells
06/01/2005EP1066376B1 Bacteria attenuated by a non-reverting mutation in each of the aroc, ompf and ompc genes, useful as vaccines
06/01/2005EP1062210B1 1,2-diazepane derivatives as interleukin-1beta converting enzyme inhibitors
06/01/2005EP0954573B1 Preparation of ionically cross-linked polyphosphazene microspheres by coacervation
06/01/2005EP0929563B1 6-o-substituted ketolides having antibacterial activity
06/01/2005EP0909327B1 Erythromycins and process for their preparation
06/01/2005EP0792358B1 A polynucleotide tuberculosis vaccine
06/01/2005CN1622957A IFNAR2 mutants, their production and use
06/01/2005CN1622946A Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
06/01/2005CN1622942A HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
06/01/2005CN1622828A Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
06/01/2005CN1622812A Prophylactic and therapeutic treatment of infectious and other diseases with immune effect compound
06/01/2005CN1622754A Novel immune effect compound
06/01/2005CN1621418A Recombinant targeted toxin against HIV-1
06/01/2005CN1621417A Antibody against SARS-CoV IgY and its preparing method
06/01/2005CN1621415A Immunoglobulin antibody against SARS-CoV and its preparing method
06/01/2005CN1621091A Intestine targeted formulation of PEGylated rotavirus and its synthesizing method
06/01/2005CN1621090A Oral freeze dried formulation of specific yelk immunoglobulin and its preparation method and usage
06/01/2005CN1621089A Method for removing endotoxin from influenza vaccine formulation
06/01/2005CN1621088A Method for removing endotoxin from influenza vaccine formulation
1 ... 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 ... 1798